Compare BGSF & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | CYPH |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 73.4M |
| IPO Year | 2013 | N/A |
| Metric | BGSF | CYPH |
|---|---|---|
| Price | $5.63 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 36.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,310,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.26 | $0.49 |
| 52 Week High | $8.20 | $3.70 |
| Indicator | BGSF | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 50.79 |
| Support Level | $5.49 | $0.58 |
| Resistance Level | $5.79 | $0.80 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 18.18 | 82.64 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.